Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?
Date
2011Author
Soysal, Teoman
Eskazan, Ahmet Emre
Erbilgin, Yücel
Ferhanoglu, Burhan
Ozbek, Ugur
Metadata
Show full item recordCollections
- Makale [92797]